CGON
NASDAQCG Oncology Inc.
Price$59.59-0.68 (-1.12%)
03:15 PM07:45 PM
News · 26 weeks480%
2025-12-212026-06-14
Mix3290d
- Insider13(41%)
- SEC Filings9(28%)
- Other8(25%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 8-K filed by CG Oncology Inc.8-K - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERSEC Form 4 filed by Director Liu Brian Guan-Chyun4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Tong Victor Edward Jr4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Mulay James4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf Susan E4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Rossi Christina4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERDirector Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $54,500 worth of shares (1,000 units at $54.50) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- PRCG Oncology to Present at Upcoming Investor Conferences in JuneDALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows: Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Presentation Time: 10:30-11:00 AM ETLocation: New York, New York Goldman Sachs 47th Annual Global Healthcare Conference Date: Tuesday, June 9, 2026Presentation Time: 2:40-3:15 PM ETLocation: Miami, Florida Interested parties may access the live audio we
- SECCG Oncology Inc. filed SEC Form 8-K: Leadership Update8-K - CG Oncology, Inc. (0001991792) (Filer)
- ANALYSTWolfe Research initiated coverage on CG OncologyWolfe Research initiated coverage of CG Oncology with a rating of Peer Perform
- PRSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardPatrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder canc
- SECSEC Form SCHEDULE 13G filed by CG Oncology Inc.SCHEDULE 13G - CG Oncology, Inc. (0001991792) (Subject)
- SECSEC Form SCHEDULE 13G filed by CG Oncology Inc.SCHEDULE 13G - CG Oncology, Inc. (0001991792) (Subject)
- PRCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months - Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced positive first results from CORE‑008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in
- PRCG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gatherin
- SECSEC Form 10-Q filed by CG Oncology Inc.10-Q - CG Oncology, Inc. (0001991792) (Filer)
- SECCG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Reports First Quarter 2026 Financial Results and Provides Business UpdatesFollowing alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported fin
- PRCG Oncology to Present at Upcoming Investor Conferences in MayDALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026Date: Tuesday, May 12, 2026Presentation Time: 10:40 AM – 11:10 AM PTLocation: Las Vegas, NV RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Presentation Time: 2:35 PM – 3:00 PM ETLocation: New York, NY Interest
- SECSEC Form DEFA14A filed by CG Oncology Inc.DEFA14A - CG Oncology, Inc. (0001991792) (Filer)
- SECSEC Form DEF 14A filed by CG Oncology Inc.DEF 14A - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERSEC Form 4 filed by Mulay James4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERSEC Form 4 filed by Bellete Ambaw4 - CG Oncology, Inc. (0001991792) (Issuer)
CGON FAQ
6 questionsWhere does CGON stock trade?
CG Oncology Inc. (CGON) is listed on NASDAQ.What sector and industry is CGON in?
CG Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did CG Oncology Inc. go public?
CG Oncology Inc. (CGON) completed its IPO in 2024.What are analysts saying about CGON?
CG Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-19. Recent price targets range from $2300.00 to $4100.00.What companies are similar to CGON?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CGON side-by-side with any of them on Quantisnow.How can I track CGON on Quantisnow?
Quantisnow aggregates CG Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGON to receive live email and push alerts on every new disclosure.